Evidence map›Paper›PMID 33914930›Full record

ArticleClinical and experimental dermatology2021

The incidence of psoriasis in Chile: an analysis of the National Waiting List Repository.

C Lecaros, J Dunstan, F Villena, D M Ashcroft, R Parisi, C E M Griffiths, S Härtel, J T Maul, C De la Cruz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

C LecarosCentre for Medical Informatics and Telemedicine, Biomedical Neuroscience Institute, ICBM, Faculty of Medicine, University of Chile, Santiago, Chile.ORCID https://orcid.org/0000-0002-8509-1188
J DunstanCentre for Medical Informatics and Telemedicine, Biomedical Neuroscience Institute, ICBM, Faculty of Medicine, University of Chile, Santiago, Chile.ORCID https://orcid.org/0000-0001-6726-7242
F VillenaCentre for Medical Informatics and Telemedicine, Biomedical Neuroscience Institute, ICBM, Faculty of Medicine, University of Chile, Santiago, Chile.ORCID https://orcid.org/0000-0002-8759-466X
D M AshcroftCentre for Pharmacoepidemiology and Drug Safety, School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.ORCID https://orcid.org/0000-0002-2958-915X
R ParisiDivision of Informatics, Imaging amd Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.ORCID https://orcid.org/0000-0002-0968-9153
C E M GriffithsDermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Manchester, UK.ORCID https://orcid.org/0000-0001-5371-4427
S HärtelCentre for Medical Informatics and Telemedicine, Biomedical Neuroscience Institute, ICBM, Faculty of Medicine, University of Chile, Santiago, Chile.ORCID https://orcid.org/0000-0002-8913-1757
J T MaulDepartment of Dermatology, University Hospital Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-9914-1545
C De la CruzPsoriasis Research Centre, Dermacross Clinic, Santiago, Chile.ORCID https://orcid.org/0000-0002-8925-0457

Funding

ANID COVID0733CMM-Basal AFB170001CORFO 16CTTS-66390DAAD 57168868DAAD 57220037Fondecyt 1181823FONDEFICM P09-015-FNational Institute for Health Research (NIHR) Manchester Biomedical Research Centre
6 · The paper itself

Abstract

backgroundPsoriasis is a serious and chronic noncommunicable disease. However, the fundamental measure of disease occurrence, the incidence, has been scarcely reported globally. There are no previous studies of psoriasis incidence in Latin America.

aimTo estimate the incidence rates of psoriasis in Chile during 2016 and 2017 using an administrative database, the Waiting List Repository.

methodsWe examined referrals of psoriasis at onset, made by physicians to dermatologists, evaluated the agreement of diagnosis, and estimated the incidence of the disease considering the eligible population at risk.

resultsIn most cases, the referrals corresponded to incident cases of psoriasis (73.3%; 95% CI: 66.6-79.2). The national incidence rates of psoriasis were 22.1 (95% CI: 21.1-23.1) and 22.7 (95% CI: 21.8-23.6) per 100 000 person-years in 2016 and 2017, respectively. The most common type of psoriasis was the late-onset type. We observed a high variation in the figures throughout the country, with a range from 0.75 (95% CI: 0.3-1.5) per 100 000 person-years in the Metropolitan region to 164.9 (95% CI: 138.6-195.1) per 100 000 person-years in the Aysen region.

conclusionWe describe for the first time the incidence of psoriasis in a Latin American country. Our findings could potentially guide collaborations to improve our global understanding of psoriasis in Latin America.

Indexed as

AdolescentAdultAgedAge DistributionChildChild, PreschoolChileFemaleHumansIncidenceInfantMaleMiddle AgedPsoriasisReferral and ConsultationSex Distribution

Identifiers

PMID33914930
PMCPMC8518053

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.